艾易舒注射液在乳腺癌术后辅助治疗中的应用及效果评价

目的: 评价艾易舒注射液对乳腺癌术后患者化疗后细胞免疫功能及毒副反应影响。方法:将70例Ⅰ～ⅢA期乳腺癌患者随机分为艾易舒加化疗组（36例）和单纯化疗组（34例），检测治疗前后T淋巴细胞亚群及NK细胞活性,比较两组的毒副反应及生活质量改变。结果: 艾易舒加化疗组患者CD3、CD4、CD8水平和CD4/CD8比值及NK细胞活性高于单纯化疗组(P<0.05)；艾易舒加化疗组患者白细胞减少程度明显小于单纯化疗组（χ²=7.44，P=0.006），其他毒副反应差异无显著性（P>0.05）；艾易舒加化疗组36.11%（13/36）患者KPS提高幅度高于单纯化疗组（11.76%，4/34）（χ²=5.64，P=0.018）; 艾易舒加化疗组44.44%患者体重增加，高于单纯化疗组（17.65%）（χ²=6.66，P=0.036）。 结论: 艾易舒注射液可作为乳腺癌患者术后化疗的辅助用药,提高免疫能力,减轻化疗的毒副反应，提高患者的生活质量。

Application of Aiyishu injection in adjuvant treatment of breast cancer after operation and curative effect evaluation

Objective To evaluate the effect of Aiyishu injection on the cellular immunity state of body and toxic and side reaction in post-operation patients with breast cancer after chemotherapy .Methods Seventy patients with breast carcinoma at stage Ⅰ-ⅢA were randomly divided into treatment group (Aiyishu associated CAF regimen) (n=36) and control group (CAF regimen) (n=34).The activities of T cells and NK cells were examined in two groups before and after treatment,and the toxic, side reaction and living quality were also compared.Results The levels of CD3,CD4,CD8 and the ratio of CD4/CD8 and the activity of NK cells in treatment group were higher than those in control group (P<0.05);the number of aleucocytosis patients in treatment group was lower than that in control group(χ2=7.44,P=0.006). In treatment group,KPS increased in 36.11%(13/36) patients,and it was higher than that in control group (11.76%,4/34)(χ2=5.64,P=0.018);44.44% patients put on weight,while 17.65% in control group(χ2=6.66,P=0.036).Conclusion Aiyishu injection can increase the ability of immunity of body and reduce the toxic and side reaction,and improre the living quality in patients with breast cancer when it is used in post operative chemotherapy of breast cancer.